Ankylosing Spondylitis: How Have Biological Therapies Affected the Market?Decision Resources
March 23, 2009
35 Pages - SKU: DECR2199569
- Array BioPharma
- Boehringer Ingelheim
- Daiichi Sankyo
- Johnson & Johnson
- Mitsubishi Tanabe
- Pfi zer
- Procter & Gamble
More Drug Discovery reports by Decision Resources
Breast Cancer in Mexico by Decision Resources
Over the next decade, the diagnosed incidence of breast cancer (CaB) in Mexico will increase at almost three times the average annual growth ...
Market Access Obstacles in the European Gout Market: Physician and Payer Perspectives on Opportunities for Novel Acute and Chronic Gout Therapies by Decision Resources
The European gout market is mature and highly genericized. First-line treatment for gout is dominated by the xanthine oxidase inhibitor allopurinol, which has ...
LaunchTrends®: Enzalutimide (Xtandi) (Wave 1) US 2012 by Decision Resources
LaunchTrends®: Xtandi (enzalutamide, formerly known as MDV-3100) is a three wave primary research study will follow the launch of Xtandi for the treatment of prostate ...
Hospital-Treated Infections by Decision ResourcesSee all reports like this >>
Hospital-treated infections (HTIs) constitute a high-value segment of the antibacterial market owing to their relatively high incidence. In addition, unlike infections treated ...
We can help you find what you need. Call us or write us:
Need help in your search?
Drug Discovery Reports